New formulations of GH delivery systems, based on novel biomaterials (see Section 4.1), have been shown to improve the bioavailability of GH and may lead to innovative therapeutic strategies for preventing and treating ovarian dysfunction [58]. This evidence concerns the gene GH1 and ovarian dysfunction.